Delving into the Latest Updates on PATH Corp. with Synapse

Overview

The purpose of this study is to evaluate the safety and tolerability of co-administration of nOPV1 + nOPV2 in infants, relative to those receiving monovalent nOPV vaccines alone and whether two and/or three doses of co-administered nOPV1 and nOPV2 are non-inferior to corresponding doses of nOPV1 alone and nOPV2 alone.

Start Date29 Sep 2025

Sponsor / Collaborator

PATH Corp.

[+3]

ISRCTN15552312

/ RecruitingNot Applicable

A mixed-method operational research study on the use of tafenoquine and G6PD testing for radical cure of Plasmodium vivax malaria in passive and active case detection in Vietnam

Start Date15 Apr 2025

Sponsor / Collaborator

PATH Corp.

NCT06879327

/ Not yet recruitingPhase 2

A Phase 2b Multicenter Randomized, Placebo-Controlled, Double-Blind, Study to Evaluate the Safety, Immunogenicity and Efficacy of R21/Matrix-M Malaria Vaccine in African Infants With Different Immunization Schedules

The aim of this study is to identify an optimal infant vaccine schedule for a malaria vaccine which is better aligned with the timing of other vaccine interventions.

Start Date02 Apr 2025

Sponsor / Collaborator

PATH Corp.

[+5]

100 Clinical Results associated with PATH Corp.

Login to view more data

0 Patents (Medical) associated with PATH Corp.

Login to view more data

100 Deals associated with PATH Corp.

Login to view more data

100 Translational Medicine associated with PATH Corp.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data